Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02079883 · ClinicalTrials.gov registry record

Ocriplasmin Research to Better Inform Treatment (ORBIT)

A clinical trial, sponsored by ThromboGenics.

Completed
Registry status
540
Enrollment target

NCT02079883 is a clinical trial that has completed, run by ThromboGenics. The registered enrollment target is 540 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02079883 has completed, sponsored by ThromboGenics.

COMPLETED
Registry status
540 participants
Enrollment target

Study Summary

This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited across approximately 120 USA retina sites.

Trial Details

FieldValue
Enrollment Target 540 participants
Start Date 2014-05
Est. Completion 2016-05

Sponsor

ThromboGenics

12 total trials

What the Registry Record Tells You About NCT02079883

The ClinicalTrials.gov registry entry for NCT02079883 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02079883 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02079883 about?

NCT02079883 is a clinical study titled "Ocriplasmin Research to Better Inform Treatment (ORBIT)". This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited acro...

What is the current status of trial NCT02079883?

This trial is currently completed. The enrollment target is 540 participants. The study started on 2014-05. Estimated completion is 2016-05.

Who is sponsoring clinical trial NCT02079883?

This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.